262 related articles for article (PubMed ID: 30081001)
1. The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy.
Brandt C; Hillmann P; Noack A; Römermann K; Öhler LA; Rageot D; Beaufils F; Melone A; Sele AM; Wymann MP; Fabbro D; Löscher W
Neuropharmacology; 2018 Sep; 140():107-120. PubMed ID: 30081001
[TBL] [Abstract][Full Text] [Related]
2. Selective inhibition of mTORC1/2 or PI3K/mTORC1/2 signaling does not prevent or modify epilepsy in the intrahippocampal kainate mouse model.
Gericke B; Brandt C; Theilmann W; Welzel L; Schidlitzki A; Twele F; Kaczmarek E; Anjum M; Hillmann P; Löscher W
Neuropharmacology; 2020 Jan; 162():107817. PubMed ID: 31654704
[TBL] [Abstract][Full Text] [Related]
3. Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex.
Theilmann W; Gericke B; Schidlitzki A; Muneeb Anjum SM; Borsdorf S; Harries T; Roberds SL; Aguiar DJ; Brunner D; Leiser SC; Song D; Fabbro D; Hillmann P; Wymann MP; Löscher W
Neuropharmacology; 2020 Dec; 180():108297. PubMed ID: 32890589
[TBL] [Abstract][Full Text] [Related]
4. Brain-penetrant PQR620 mTOR and PQR530 PI3K/mTOR inhibitor reduce huntingtin levels in cell models of HD.
Singer E; Walter C; Fabbro D; Rageot D; Beaufils F; Wymann MP; Rischert N; Riess O; Hillmann P; Nguyen HP
Neuropharmacology; 2020 Jan; 162():107812. PubMed ID: 31622602
[TBL] [Abstract][Full Text] [Related]
5. Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders.
Rageot D; Bohnacker T; Melone A; Langlois JB; Borsari C; Hillmann P; Sele AM; Beaufils F; Zvelebil M; Hebeisen P; Löscher W; Burke J; Fabbro D; Wymann MP
J Med Chem; 2018 Nov; 61(22):10084-10105. PubMed ID: 30359003
[TBL] [Abstract][Full Text] [Related]
6. The mTOR inhibitor rapamycin has limited acute anticonvulsant effects in mice.
Hartman AL; Santos P; Dolce A; Hardwick JM
PLoS One; 2012; 7(9):e45156. PubMed ID: 22984623
[TBL] [Abstract][Full Text] [Related]
7. Dual inhibition of the mTORC1 and mTORC2 signaling pathways is a promising therapeutic target for adult T-cell leukemia.
Kawata T; Tada K; Kobayashi M; Sakamoto T; Takiuchi Y; Iwai F; Sakurada M; Hishizawa M; Shirakawa K; Shindo K; Sato H; Takaori-Kondo A
Cancer Sci; 2018 Jan; 109(1):103-111. PubMed ID: 29077243
[TBL] [Abstract][Full Text] [Related]
8. Cannabidiol Elevates Mechanistic Target of Rapamycin Inhibitor Levels in Patients With Tuberous Sclerosis Complex.
Ebrahimi-Fakhari D; Agricola KD; Tudor C; Krueger D; Franz DN
Pediatr Neurol; 2020 Apr; 105():59-61. PubMed ID: 31924480
[TBL] [Abstract][Full Text] [Related]
9. Targeting mTORC1/2 Complexes Inhibit Tumorigenesis and Enhance Sensitivity to 5-Flourouracil (5-FU) in Hepatocellular Carcinoma: A Preclinical Study of mTORC1/2-Targeted Therapy in Hepatocellular Carcinoma (HCC).
Zhang Y; Jia QA; Kadel D; Zhang XF; Zhang QB
Med Sci Monit; 2018 May; 24():2735-2743. PubMed ID: 29720580
[TBL] [Abstract][Full Text] [Related]
10. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.
Curatolo P
Pediatr Neurol; 2015 Mar; 52(3):281-9. PubMed ID: 25591831
[TBL] [Abstract][Full Text] [Related]
11. Effects of antiepileptic drugs in a new TSC/mTOR-dependent epilepsy mouse model.
Koene LMC; van Grondelle SE; Proietti Onori M; Wallaard I; Kooijman NHRM; van Oort A; Schreiber J; Elgersma Y
Ann Clin Transl Neurol; 2019 Jul; 6(7):1273-1291. PubMed ID: 31353861
[TBL] [Abstract][Full Text] [Related]
12. Preclinical analysis of MTOR complex 1/2 inhibition in diffuse intrinsic pontine glioma.
Flannery PC; DeSisto JA; Amani V; Venkataraman S; Lemma RT; Prince EW; Donson A; Moroze EE; Hoffman L; Levy JMM; Foreman N; Vibhakar R; Green AL
Oncol Rep; 2018 Feb; 39(2):455-464. PubMed ID: 29207163
[TBL] [Abstract][Full Text] [Related]
13. Dual Targeting by Inhibition of Phosphoinositide-3-Kinase and Mammalian Target of Rapamycin Attenuates the Neuroinflammatory Responses in Murine Hippocampal Cells and Seizures in C57BL/6 Mice.
Vyas P; Tulsawani R; Vohora D
Front Immunol; 2021; 12():739452. PubMed ID: 34887852
[TBL] [Abstract][Full Text] [Related]
14. Everolimus is better than rapamycin in attenuating neuroinflammation in kainic acid-induced seizures.
Yang MT; Lin YC; Ho WH; Liu CL; Lee WT
J Neuroinflammation; 2017 Jan; 14(1):15. PubMed ID: 28109197
[TBL] [Abstract][Full Text] [Related]
15. Preclinical efficacy of dual mTORC1/2 inhibitor AZD8055 in renal cell carcinoma harboring a TFE3 gene fusion.
Kauffman EC; Lang M; Rais-Bahrami S; Gupta GN; Wei D; Yang Y; Sourbier C; Srinivasan R
BMC Cancer; 2019 Sep; 19(1):917. PubMed ID: 31519159
[TBL] [Abstract][Full Text] [Related]
16. Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects.
Jhanwar-Uniyal M; Amin AG; Cooper JB; Das K; Schmidt MH; Murali R
Adv Biol Regul; 2017 May; 64():39-48. PubMed ID: 28189457
[TBL] [Abstract][Full Text] [Related]
17. Diverse signaling mechanisms of mTOR complexes: mTORC1 and mTORC2 in forming a formidable relationship.
Jhanwar-Uniyal M; Wainwright JV; Mohan AL; Tobias ME; Murali R; Gandhi CD; Schmidt MH
Adv Biol Regul; 2019 May; 72():51-62. PubMed ID: 31010692
[TBL] [Abstract][Full Text] [Related]
18. Everolimus in tuberous sclerosis patients with intractable epilepsy: a treatment option?
Wiegand G; May TW; Ostertag P; Boor R; Stephani U; Franz DN
Eur J Paediatr Neurol; 2013 Nov; 17(6):631-8. PubMed ID: 23845174
[TBL] [Abstract][Full Text] [Related]
19. Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors.
Salazar R; Garcia-Carbonero R; Libutti SK; Hendifar AE; Custodio A; Guimbaud R; Lombard-Bohas C; Ricci S; Klümpen HJ; Capdevila J; Reed N; Walenkamp A; Grande E; Safina S; Meyer T; Kong O; Salomon H; Tavorath R; Yao JC
Oncologist; 2018 Jul; 23(7):766-e90. PubMed ID: 29242283
[TBL] [Abstract][Full Text] [Related]
20. Phosphorylation of mTOR Ser2481 is a key target limiting the efficacy of rapalogs for treating hepatocellular carcinoma.
Watari K; Nishitani A; Shibata T; Noda M; Kawahara A; Akiba J; Murakami Y; Yano H; Kuwano M; Ono M
Oncotarget; 2016 Jul; 7(30):47403-47417. PubMed ID: 27329724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
